We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Cipher Pharmaceuticals Inc | TSX:CPH | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.68 | 8.65 | 9.13 | 0 | 12:01:06 |
From May 2021 to May 2024
MISSISSAUGA, ON, March 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial and operating results for the three and twelve months ended December 31, 2021 after market close on March 17, 2022. The Company will also host a conference call on Friday, March 18, 2022 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS |
DATE: March 18, 2022 |
TIME: 8:30 a.m. ET |
DIAL-IN NUMBER: (647) 794-4605 or (888) 204-4368 |
CONFERENCE ID: 1673781 |
REPLAY DIAL-IN: (888) 203-1112 (playback 1673781#) |
Expires March 25, 2022 |
WEBCAST: https://produceredition.webcasts.com/starthere.jsp?ei=1533942&tp_key=62d3cb0b34 |
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
Copyright 2022 Canada NewsWire
1 Year Cipher Pharmaceuticals Chart |
1 Month Cipher Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
